352 material Form 8-K filings that 310 companies we cover made with the SEC in August 2024, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Gap Inc. reported second-quarter fiscal 2024 net sales of $3.7 billion, up 5% from a year earlier, with diluted earnings per share of $0.54 versus $0.32. The company raised its fiscal 2024 outlook for gross margin expansion and operating income growth while reaffirming its net sales and operating expense outlook, which points to stronger profitability expectations for shareholders.
Net sales of $3.7 billion, up 5%; comparable sales up 3% for the quarter ended August 3, 2024.
Operating income of $293 million versus $106 million a year earlier; net income of $206 million.
Diluted EPS of $0.54 versus $0.32 in the prior-year quarter.
Fiscal 2024 outlook: gross margin expansion of approximately 200 basis points (prior: at least 150); operating income growth in the mid to high 50% range (prior: mid 40% range).
CAVA Group reported results for the fiscal second quarter ended July 14, 2024, with CAVA revenue up 35.2% to $231.4 million and net income of $19.7 million, compared with $6.5 million a year earlier. The company also raised its fiscal 2024 guidance, lifting Adjusted EBITDA to $109.0 million to $114.0 million from $100.0 million to $105.0 million, which indicates a higher expected profit outlook for shareholders.
Net income was $19.7 million, or $0.17 per diluted share, versus $6.5 million, or $0.21 per diluted share, in the prior year quarter; diluted weighted-average shares rose to 118.3 million from 31.3 million.
CAVA same restaurant sales grew 14.4%, including 9.5% from guest traffic; the company opened 18 net new restaurants, bringing the total to 341.
Fiscal 2024 CAVA same restaurant sales growth guidance was raised to 8.5% to 9.5% from 4.5% to 6.5%, and Adjusted EBITDA guidance to $109.0 million to $114.0 million from $100.0 million to $105.0 million.
Restaurant-level profit margin was 26.5%, up from 26.1% a year earlier; the company cited a June 3 launch of grilled steak as a partial offset to margin gains.
Artivion reported second-quarter 2024 revenue of $98.0 million, up 10% from $89.3 million a year earlier, and a net loss of $2.1 million ($0.05 per diluted share), narrower than the $3.4 million loss ($0.08 per share) in the prior-year quarter. The company raised its full-year 2024 revenue and adjusted EBITDA guidance, though the increases at the midpoint are small.
Q2 2024 revenue $98.0 million vs. $89.3 million in Q2 2023, up 10% on both GAAP and constant currency bases
Q2 2024 net loss of $2.1 million ($0.05 per diluted share) vs. net loss of $3.4 million ($0.08 per share) in Q2 2023; non-GAAP net income $2.9 million ($0.07 per share)
Adjusted EBITDA rose 35% to $18.6 million from $13.8 million
FY24 revenue guidance raised to $388 million to $396 million from $386 million to $396 million; adjusted EBITDA guidance raised to $69 million to $72 million from $68 million to $72 million
YETI reported second-quarter 2024 net sales up 15% to $463.5 million, or 9% on an adjusted basis that excludes a 2023 recall reserve adjustment, and GAAP diluted EPS of $0.59, up from $0.44. The company raised its fiscal 2024 adjusted sales growth outlook to 8% to 10% and its adjusted EPS outlook to $2.61 to $2.65, which matters to shareholders because it signals higher expected profit for the year.
Net sales rose 15% to $463.5 million; adjusted net sales rose 9% after excluding the $24.5 million unfavorable recall reserve impact in the prior-year quarter.
GAAP diluted EPS was $0.59 versus $0.44; adjusted EPS was $0.70 versus $0.57.
Fiscal 2024 adjusted EPS outlook raised to $2.61 to $2.65, from $2.49 to $2.62 previously.
Cash was $212.9 million at June 29, 2024, and $200 million remained under the share repurchase program.
Maximus reported fiscal third-quarter 2024 revenue of $1.31 billion, up 10.6% from a year earlier, and diluted earnings per share of $1.46 versus $0.50. The company raised its fiscal 2024 guidance for a third consecutive time, with adjusted diluted EPS now expected at $6.00 to $6.20, which points to stronger earnings for shareholders.
Q3 FY2024 revenue rose 10.6% to $1.31 billion; diluted EPS was $1.46 versus $0.50 a year earlier
Adjusted diluted EPS was $1.74 versus $0.78 in the prior-year quarter
FY2024 guidance: revenue $5.25 billion to $5.35 billion; adjusted diluted EPS $6.00 to $6.20; free cash flow $350 million to $380 million
Quarterly dividend of $0.30 per share is payable August 31, 2024
Dutch Bros reported second-quarter 2024 results on August 7, 2024, with total revenue up 30.0% year over year and net income rising to $22.2 million from $9.7 million. The company raised its 2024 revenue and Adjusted EBITDA guidance and lowered its capital expenditure range, which indicates higher expected operating results for shareholders.
Total revenues were $324.9 million, up 30.0% from $249.9 million a year earlier.
Net income was $22.2 million, or $0.12 per diluted share, versus $9.7 million, or $0.05, in Q2 2023.
2024 total revenue guidance was raised to $1.215 billion to $1.230 billion, from $1.20 billion to $1.215 billion.
2024 Adjusted EBITDA guidance was raised to $200 million to $210 million, from $195 million to $205 million.
Boot Barn reported first-quarter fiscal 2025 net sales up 10.3% to $423.4 million and diluted EPS of $1.26, up from $1.13 a year earlier. The company also replaced its prior fiscal 2025 guidance, raising the expected diluted EPS range to $5.05 to $5.35 from a prior high end of $4.85, which signals higher expected profit for shareholders.
Q1 net sales rose 10.3% to $423.4 million; consolidated same store sales rose 1.4%, with e-commerce up 6.7%.
Q1 net income was $38.9 million, or $1.26 per diluted share, versus $34.3 million, or $1.13, a year earlier, including a benefit of about $0.06 per share from share-based compensation tax accounting.
Fiscal 2025 net sales guidance is $1.816 billion to $1.850 billion, versus a prior high end of $1.800 billion; income from operations guidance is $207.0 million to $219.4 million.
Second-quarter guidance calls for total sales of $405 million to $412 million and diluted EPS of $0.81 to $0.87.
Sabra Health Care REIT reported second-quarter 2024 net income of $0.10 per diluted share, up from $0.09 a year earlier, and raised its 2024 earnings guidance ranges. The company also declared a quarterly dividend of $0.30 per share, which matters to shareholders because it reflects both higher reported earnings and the updated outlook.
Q2 2024 net income was $0.10 per diluted share versus $0.09 in Q2 2023; FFO was $0.35 versus $0.32
2024 guidance raised: net income $0.48-$0.51, Normalized FFO $1.36-$1.39, Normalized AFFO $1.41-$1.44 per diluted share
Quarterly dividend of $0.30 per share declared August 7, 2024, payable August 30, 2024 to holders of record on August 19, 2024
Net Debt to Adjusted EBITDA was 5.45x as of June 30, 2024; liquidity was approximately $906.0 million
Rockwell Automation reported fiscal third-quarter 2024 sales of $2.05 billion, down 8.4% from a year earlier, and diluted EPS of $2.02, down from $3.45. The company lowered its fiscal 2024 guidance, citing customer project delays tied to weaker consumer demand, high interest rates, and policy uncertainty.
Q3 sales were $2,051 million, down 8.4% from $2,239 million; organic sales also fell 8.4%.
Diluted EPS was $2.02 versus $3.45, and adjusted EPS was $2.71, down 10.0%; diluted EPS includes a $0.46 restructuring charge.
Fiscal 2024 diluted EPS guidance was cut to about $8.32 from $8.80-$9.80; adjusted EPS guidance is now about $9.60 versus $10.00-$11.00.
Reported sales growth guidance was cut to about (8.5)% from (6.0)%-(4.0)%; total ARR rose 17%.
Reynolds Consumer Products reported second-quarter 2024 net revenues of $930 million, down from $940 million a year earlier, while net income rose to $97 million from $66 million and EPS reached $0.46 versus $0.32. The company raised its full-year 2024 net revenue, net income, Adjusted EBITDA and EPS guidance and issued third-quarter 2024 guidance, which points to higher expected profit despite slightly lower sales.
Q2 2024 net revenues were $930 million versus $940 million in Q2 2023, with retail net revenues up 1% to $892 million.
Q2 2024 net income was $97 million versus $66 million, and Adjusted EBITDA was $172 million versus $150 million.
Full-year 2024 Adjusted EBITDA guidance was raised to $670 million to $685 million from $660 million to $680 million, and EPS guidance to $1.65 to $1.71 from $1.62 to $1.70.
The board approved a quarterly dividend of $0.23 per share, payable August 30, 2024, and a $50 million term loan prepayment was made after quarter end.
National Vision reported second-quarter 2024 net revenue from continuing operations of $451.7 million, up 4.6%, but swung to a net loss from continuing operations of $(1.0) million, compared with income of $3.6 million a year earlier. The company revised its fiscal 2024 outlook downward, with CEO Reade Fahs saying sales needed a greater inflection to deliver the originally expected results. For shareholders, the lower guidance and new transformation actions signal that the company expects slower progress than previously planned.
Q2 2024 net revenue from continuing operations rose 4.6% to $451.7 million; diluted EPS from continuing operations was $(0.01), versus $0.05 a year earlier
Q2 2024 Adjusted Operating Income rose 13.8% to $14.1 million; Adjusted Diluted EPS was $0.15 versus $0.12
Updated fiscal 2024 outlook (as of August 7, 2024) lowers net revenue to $1.820 billion to $1.840 billion and Adjusted Operating Income to $57 million to $62 million, versus prior continuing-operations ranges of $1.825 billion to $1.865 bil
Company is reviewing all stores to optimize its fleet; Alex Wilkes to become President effective August 19, 2024
Veracyte reported second-quarter 2024 total revenue of $114.4 million, up 27% from $90.3 million a year earlier, and swung to net income of $5.7 million from a net loss of $8.4 million. The company raised its full-year 2024 total revenue guidance to $432 million to $438 million from $402 million to $410 million, which is a positive signal for shareholders.
Q2 2024 total revenue was $114.4 million, up 27% from $90.3 million in Q2 2023; testing revenue rose 31% to $107.0 million.
Net income was $5.7 million, or $0.07 per diluted share, versus a net loss of $8.4 million, or $(0.12) per share, in Q2 2023.
Adjusted EBITDA was $24.0 million, or 21% of revenue, compared with $11.0 million, or 12% of revenue, a year earlier.
Full-year 2024 total revenue guidance rose to $432 million to $438 million; year-end cash guidance rose to $260 million to $270 million.
Progyny reported second-quarter 2024 revenue of $304.1 million, up 8.8%, with net income of $16.5 million and Adjusted EBITDA of $54.5 million, up 15%. The company said revenue per utilizing member is running below its expectations and revised its second-half outlook, now projecting full-year 2024 revenue of $1.165 billion to $1.20 billion. The board also authorized an additional $100 million share repurchase, which matters to shareholders because the outlook is softer even as profit and buybacks grew.
Q2 2024 revenue was $304.1 million, up 8.8%, and net income was $16.5 million, or $0.17 per diluted share, versus $0.15 a year earlier
Adjusted EBITDA was $54.5 million, up 15%, with an Adjusted EBITDA margin of 17.9%
Full-year 2024 revenue is now projected at $1.165 billion to $1.20 billion; third-quarter revenue is projected at $290.0 million to $303.0 million
On August 5, 2024, the board authorized an additional $100 million of share repurchases, after the company bought 5,593,128 shares for $159.8 million in the second quarter
TG Therapeutics reported second-quarter 2024 total revenue of $73.5 million, up from $16.1 million a year earlier, and net income of $6.9 million compared with a net loss of $47.6 million in the same period of 2023. The company raised its full-year 2024 U.S. BRIUMVI net revenue target to $290 million to $300 million from $270 million to $290 million, and authorized a share buyback of up to $100 million funded by a new $250 million term loan that repaid its Hercules debt.
Q2 2024 total revenue was $73.5 million versus $16.1 million in Q2 2023; diluted EPS was $0.04 versus $(0.34).
Full-year 2024 U.S. BRIUMVI net revenue target raised to $290 million to $300 million from $270 million to $290 million.
$250 million term loan with Blue Owl Capital and HealthCare Royalty matures August 2, 2029; proceeds repaid Hercules debt, and the Board authorized up to $100 million in share repurchases.
Audit Committee concluded a 2021 stock-grant expense error reflects a material weakness in internal control as of December 31, 2023; a 10-K/A will follow, and the company states there are no financial changes to the 2023 annual report.
Cabot reported third-quarter fiscal 2024 results on August 5, 2024, with adjusted EPS of $1.92, up 35% from $1.42, and net sales of $1,016 million, up from $968 million. The company raised its fiscal 2024 adjusted EPS guidance to $7.00 to $7.10 from $6.65 to $6.85, which points to higher expected profit for the full year.
Diluted EPS of $1.94 versus $1.43 a year earlier; adjusted EPS of $1.92 versus $1.42
Net sales and other operating revenues of $1,016 million versus $968 million in the same quarter last year
Fiscal 2024 adjusted EPS guidance raised to $7.00 to $7.10 from $6.65 to $6.85
Returned $73 million to shareholders in the quarter, including $24 million in dividends and $49 million in share repurchases
Apple Hospitality REIT reported second-quarter 2024 net income of $73.9 million, up 13.2% from a year earlier, and EPS of $0.31 versus $0.29. The company also lowered its 2024 outlook, decreasing net income guidance by $6 million and Adjusted EBITDAre guidance by $7 million at the midpoint, which lowers the expected earnings for shareholders.
Q2 2024 net income was $73.9 million versus $65.3 million in Q2 2023; EPS was $0.31 versus $0.29.
Adjusted EBITDAre was $140.9 million, up 9.1%; MFFO was $121.3 million, up 8.9%.
Updated 2024 guidance: net income of $202 million to $225 million and Adjusted EBITDAre of $456 million to $474 million, with Comparable Hotels RevPAR change cut by 150 bps at the midpoint.
Preliminary July 2024 Comparable Hotels occupancy was approximately 77%, flat versus July 2023, with ADR down slightly.
Palomar Holdings reported second quarter 2024 net income of $25.7 million, or $1.00 per diluted share, up from $17.6 million, or $0.69, a year earlier, with gross written premiums up 40.4% to $385.2 million. The company raised its full-year 2024 adjusted net income guidance to $124 million to $130 million, which includes catastrophe losses from Hurricanes Beryl and Debby. For shareholders, the filing shows higher profit and a higher outlook for the year.
Q2 2024 net income was $25.7 million, or $1.00 per diluted share, versus $17.6 million, or $0.69, in Q2 2023.
Adjusted net income was $32.0 million, or $1.25 per diluted share, versus $21.8 million, or $0.86, in Q2 2023.
Full-year 2024 adjusted net income guidance is now $124 million to $130 million.
Gross written premiums rose 40.4% to $385.2 million; the combined ratio was 79.1%, compared with 79.0% a year earlier.
Interface reported second quarter 2024 net sales of $346.6 million, up 5.2% from the prior year, and GAAP diluted earnings per share of $0.38 versus $0.27. The company increased its full fiscal 2024 net sales estimate to $1.30 billion to $1.32 billion, which gives shareholders a higher company-issued sales forecast for the year.
Q2 2024 net sales $346.6 million, up 5.2% versus $329.6 million a year earlier
GAAP diluted EPS $0.38 versus $0.27; adjusted diluted EPS $0.40 versus $0.25
Full-year 2024 net sales outlook of $1.30 billion to $1.32 billion; Q3 2024 net sales outlook of $330 million to $340 million
Currency neutral orders up 8% year-over-year in Q2 2024
Regency Centers reported second-quarter 2024 results on August 1, 2024, with net income attributable to common shareholders of $0.54 per diluted share, up from $0.51 a year earlier. The REIT raised its full-year 2024 Nareit FFO guidance to $4.21 to $4.25 per diluted share from $4.15 to $4.21, which signals higher expected operating results for shareholders.
Q2 2024 Nareit FFO was $1.06 per diluted share, up from $1.03 in Q2 2023; Core Operating Earnings was $1.02, up from $0.96.
2024 Nareit FFO guidance raised to $4.21 to $4.25 per diluted share; Core Operating Earnings guidance raised to $4.06 to $4.10.
Same Property NOI rose 3.3% excluding lease termination fees and collection of 2020-2021 reserves; Same Property percent leased was 95.8%.
On July 31, 2024, the board authorized a new share repurchase program of up to $250 million and declared a $0.67 quarterly common dividend.
LeMaitre Vascular reported preliminary second-quarter 2024 results, with sales of $55.8 million, up 11% from a year earlier, and net income of $11.8 million, up 46%. The company raised its full-year 2024 guidance, now projecting sales of $216.8 million to $220.8 million and EPS of $1.82 to $1.91, which shareholders will weigh alongside the company's higher quarterly profitability.
Q2 2024 sales $55.8 million, up 11% (12% organic); diluted EPS $0.52, up 44%
Gross margin 68.9%, up from 64.0% in Q2 2023; operating income $14.4 million, up 52%
Full-year 2024 guidance: sales $216.8 million to $220.8 million; EPS $1.82 to $1.91
Quarterly dividend of $0.16 per share payable August 29, 2024, to holders of record August 15, 2024
Bio-Rad reported second-quarter 2024 net sales of $638.5 million, down 6.3% from a year earlier, and a GAAP net loss of $2,165.5 million, driven by a change in the fair market value of its Sartorius AG investment. The company lowered its full-year 2024 outlook, now expecting non-GAAP revenue to decline 2.5% to 4.0% on a currency-neutral basis, and its board raised the buyback authorization by $500 million.
Q2 2024 net sales were $638.5 million, down 6.3% from $681.1 million; Life Science fell 16.5% and Clinical Diagnostics rose 2.1%.
GAAP net loss was $2,165.5 million, or $76.26 per diluted share, versus a loss of $39.59 per share a year earlier; non-GAAP EPS was $3.11 versus $3.00.
Full-year 2024 non-GAAP revenue outlook moved to a 2.5% to 4.0% decline from prior 1.0% to 2.5% growth; non-GAAP operating margin outlook cut to 12.0% to 13.0% from 13.5% to 14.0%.
On July 29, 2024, the board authorized up to an additional $500 million in repurchases; about $578 million was available as of July 31, 2024.
Universal Display reported second quarter 2024 revenue of $158.5 million, up from $146.6 million a year earlier, and net income of $52.3 million, or $1.10 per diluted share, versus $1.04 a year earlier. The company raised the lower end of its 2024 revenue guidance to a range of $645 million to $675 million, while operating income and gross margin both declined year over year.
Q2 2024 total revenue was $158.5 million, compared with $146.6 million in Q2 2023.
Q2 2024 net income was $52.3 million, or $1.10 per diluted share, compared with $49.7 million, or $1.04 per diluted share.
Operating income fell to $56.4 million from $58.6 million, and total gross margin was 76% versus 78%.
2024 revenue guidance is now $645 million to $675 million; the company also declared a third quarter dividend of $0.40 per share, payable September 30, 2024.
Dorman Products reported second-quarter 2024 net sales of $503.0 million, up 4.7%, and diluted EPS of $1.53, up 47% from a year earlier. The company raised its full-year 2024 diluted EPS guidance to $5.32 to $5.52, from $4.71 to $5.01, which gives shareholders a higher profit outlook. Heavy Duty and Specialty Vehicle sales declined in the quarter.
Net sales were $503.0 million, up 4.7% from $480.6 million; Light Duty rose 9%, while Heavy Duty fell 11% and Specialty Vehicle fell 2%.
Diluted EPS was $1.53 versus $1.04; adjusted diluted EPS was $1.67 versus $1.01.
2024 diluted EPS guidance was raised to $5.32 to $5.52 from $4.71 to $5.01; adjusted diluted EPS guidance is $6.00 to $6.20.
The company repurchased $25 million of its shares and will hold a conference call on August 2, 2024 at 8:00 a.m. Eastern.
Tanger reported second-quarter 2024 results and raised its full-year 2024 Core FFO guidance to $2.05 to $2.12 per share from $2.03 to $2.11. Core FFO and FFO per share both rose to $0.53 from $0.47, while diluted net income per share slipped to $0.22 from $0.23. The higher guidance and rising funds from operations point to improved operating results for shareholders.
Q2 2024 total revenues were $129.0 million, compared with $110.6 million in Q2 2023.
Q2 2024 diluted net income per share was $0.22, versus $0.23 a year earlier; FFO and Core FFO were $0.53 per share, versus $0.47.
Full-year 2024 Core FFO guidance rose to $2.05 to $2.12 per share from $2.03 to $2.11.
Board authorized a quarterly cash dividend of $0.275 per share, payable August 15, 2024.
Alignment Healthcare reported second-quarter 2024 revenue of $681.3 million, up 47.3% from a year earlier, and a net loss of $24.0 million, narrowed from $28.5 million. The company raised its year-end membership and revenue guidance and kept its full-year adjusted gross profit and adjusted EBITDA guidance unchanged, which shows the larger revenue base is also producing a smaller loss.
Total revenue was $681.3 million, up 47.3% year over year, and health plan membership was about 175,100, up 56.1%.
Adjusted EBITDA was $6.0 million, compared with a loss of $2.1 million a year earlier; net loss was $24.0 million versus $28.5 million.
Full-year 2024 revenue guidance was raised to $2.61 billion to $2.64 billion, and year-end membership guidance was raised to 178,000 to 180,000.
Full-year adjusted gross profit ($280 million to $310 million) and adjusted EBITDA (–$12 million to $12 million) guidance was maintained.
Schneider National reported second quarter 2024 operating revenues of $1,316.7 million, down 2% from $1,346.5 million a year earlier, while income from operations fell 51% to $51.0 million and diluted EPS dropped to $0.20 from $0.43. The company also lowered its full-year 2024 adjusted diluted EPS guidance to $0.80-$0.90 from $0.85-$1.00, citing slower-than-expected pricing gains, which signals weaker profit expectations for shareholders.
Q2 2024 income from operations was $51.0 million versus $103.8 million in Q2 2023; diluted EPS was $0.20 versus $0.43.
Full-year 2024 adjusted diluted EPS guidance was cut to $0.80-$0.90 from $0.85-$1.00.
Net capital expenditures guidance was lowered to $300.0-$350.0 million from $350.0-$400.0 million.
Q2 2024 free cash flow was $112.9 million, compared with negative $57.1 million in Q2 2023.
IDACORP reported second quarter 2024 net income attributable to IDACORP of $89.5 million, or $1.71 per diluted share, up from $68.6 million, or $1.35 per diluted share, a year earlier. The company raised the low end of its full-year 2024 earnings guidance to $5.30 to $5.45 per diluted share from $5.25 to $5.45, citing higher customer usage, customer growth and rate changes, partly offset by higher depreciation.
Q2 2024 net income $89.5 million ($1.71 per diluted share) vs. $68.6 million ($1.35) in Q2 2023
Six-month 2024 earnings $2.67 per diluted share vs. $2.46 in the first half of 2023
2024 earnings guidance now $5.30 to $5.45 per diluted share vs. previous $5.25 to $5.45, as of August 1, 2024
Idaho Power expects to use $35 million to $50 million of additional tax credits in 2024, with the range previously $35 million to $60 million
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.